Medtronic picks up a CE mark for its next-gen pacemaker

Medtronic ($MDT) has launched its latest pacemaker in Europe, picking up CE mark clearance for Viva CRT-P, a device it touts as improving patient response rates. The implant, a cardiac resynchronization therapy pacemaker, is outfitted with Medtronic's AdaptivCRT software, an algorithm-based technology designed to automatically adjust pacing to patients' specific heart function. In clinical trials, the software demonstrated a 21% reduction in heart failure hospitalization and a 46% decline in risk of atrial fibrillation, according to Medtronic. More

Suggested Articles

The FDA disclosed over 60 safety reports related to intra-aortic balloon pumps manufactured by Maquet and Datascope, following a recall this summer.

Truvian Sciences raised $27.1 million to fuel the development of its benchtop blood tester, bringing the company’s total funding to $46.3 million.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.